Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIa, Multi-centre, Randomized, Double-Blind, Double-Dummy, Active and Placebo Controlled, Parallel Group Study to Assess the Effectiveness and Safety of AZD2066 After 6 Weeks of Treatment in Patients With Major Depressive Disorder - D0475C00020

NCT01145755 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT01145755
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01145755 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIa, Multi-centre, Randomized, Double-Blind, Double-Dummy, Active and Placebo Controlled, Parallel Group Study to Assess the Effectiveness and Safety of AZD2066 After 6 Weeks of Treatment in Patients With Major Depressive Disorder - D0475C00020
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Terminated
Start date
May 31, 2010
Completion date
November 30, 2010
Enrollment
131 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

major depressive disorder